HT
PVLA

HAP Trading’s Palvella Therapeutics PVLA Stock Holding History

HAP Trading’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-150
Closed -$13K – 2925
2021
Q3 		$13K Sell
150
-166
-53% -$57.8K ﹤0.01% 1942
2021
Q2 		$38K Buy
+316
New +$69.3K ﹤0.01% 1574

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HAP Trading's PVLA Position: Q4 2019 in Review

HAP Trading sold out of Palvella Therapeutics (PVLA) in Q4 2019, closing a stake of 1,163 shares — an estimated $317K sold.

HAP Trading first reported a position in PVLA in Q3 2019 and held it in 1 quarter. The position peaked at $317K in Q3 2019. 97 funds tracked by Wall St. Rank hold PVLA as of Q4 2019.

  • HAP Trading reported no remaining Palvella Therapeutics position as of Q4 2019 after selling out during the quarter.
  • HAP Trading sold 1,163 Palvella Therapeutics shares in Q4 2019, an estimated $317K.
  • HAP Trading first reported a position in Palvella Therapeutics in Q3 2019 and held it in 1 quarter.
  • HAP Trading's Palvella Therapeutics position peaked at $317K in Q3 2019.
  • 97 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2019.

Based on HAP Trading's 13F filing for Q4 2019, filed 11 Feb 2020.